Evotec SE (EVO)

NMS – Real vaqt narxi. Valyuta: USD

3.00

-0.06 (-1.96%)

Yopilishda: May 12, 2026, 4:00 PM EDT

2.72

-0.28 (-9.33%)

Bozor oldidan: May 13, 2026, 6:05 AM EDT

06.05.2026

Evotec SE (EVO) Q1 2026 Earnings Call Transcript

04.05.2026

Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall

Joint Evotec-Almirall team advances small molecule program to preclinical development significantly outperforming standard industry timelines Collaboration leverages Evotec's end-to-end integrated AI/ML-driven R&D capabilities and Almirall's dermatology expertise HAMBURG, DE / ACCESS Newswire / May 4, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the nomination of a small molecule preclinical development candidate (PDC) from its multi‑target drug discovery alliance in medical dermatology with Almirall S.A. The program is aimed at developing novel treatments for immune‑mediated inflammatory skin diseases with high unmet medical need.

30.04.2026

Evotec Receives Grants to Advance Tuberculosis Treatment

Grants support discovery and development of novel drug candidates and evaluation and prioritization of advanced drug regimens for clinical testing New funding from the Gates Foundation extends Evotec's commitment to create more effective tuberculosis treatment regimens HAMBURG, GERMANY / ACCESS Newswire / April 30, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced that it has received two grants from the Gates Foundation for drug discovery and translation in tuberculosis (TB), following four earlier TB grants from the foundation, amounting to $4.9 million over 25 months and $5 million over 24 months. The new funding underscores Evotec's commitment to translating innovative science into impactful therapies addressing high-priority public health threats.

29.04.2026

Evotec Announces New Nomination to Board of Directors

Nomination of Dr. Wolfgang Hofmann as independent Supervisory Board member to further strengthen oversight and governance capabilities Conclusion of cooperation agreement with MAK Capital following constructive discussions, reflecting Evotec's commitment to open shareholder dialogue Annual General Meeting to vote on the appointments of Supervisory Board members and proposed expansion of Supervisory Board, supporting effective oversight and long‑term value creation HAMBURG, GERMANY / ACCESS Newswire / April 29, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt:EVT) today announced the nomination of Dr. Wolfgang Hofmann for election as an independent member of the Supervisory Board at the company's upcoming Annual General Meeting (AGM) to be held on June 11, 2026. The AGM agenda also includes the previously announced nomination of Dieter Weinand as Chairman of the Supervisory Board, as well as a proposal to increase the size of the Supervisory Board from six to seven members.

29.04.2026

Evotec SE to Announce First Quarter 2026 Results on May 6, 2026

HAMBURG, DE / ACCESS Newswire / April 29, 2026 / Evotec SE (NASDAQ:EVO; Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first quarter 2026 and provide a business update on Wednesday, May 6, 2026. The conference call will be held in English.

15.04.2026

Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer

Will play key role in strengthening cross-functional execution in support of global platform, scientific capabilities and partner delivery as well as the execution of the Horizon initiative Brings more than 20 years of international leadership experience across operations, transformation, strategy, supply, procurement and R&D integration HAMBURG, DE / ACCESS Newswire / April 15, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Dr. Ingrid Müller as Chief Operating Officer (COO). Dr. Müller will be joining Evotec's Management Board, effective May 1, 2026.

08.04.2026

Evotec SE (EVO) Q4 2025 Earnings Call Transcript

Videolar

No Data

There is no data to display

Press-relizlar

04.05.2026

Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall

30.04.2026

Evotec Receives Grants to Advance Tuberculosis Treatment

29.04.2026

Evotec Announces New Nomination to Board of Directors

15.04.2026

Evotec SE (EVO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Evotec SE (EVO)

Evotec SE (EVO) Q1 2026 Earnings Call Transcript

Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall

Evotec Receives Grants to Advance Tuberculosis Treatment

Evotec Announces New Nomination to Board of Directors

Evotec SE to Announce First Quarter 2026 Results on May 6, 2026

Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer

Evotec SE (EVO) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall

Evotec Receives Grants to Advance Tuberculosis Treatment

Evotec Announces New Nomination to Board of Directors

Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer

Evotec SE (EVO) Q1 2026 Earnings Call Transcript

Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall

Evotec Receives Grants to Advance Tuberculosis Treatment

Evotec Announces New Nomination to Board of Directors

Evotec SE to Announce First Quarter 2026 Results on May 6, 2026

Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer

Evotec SE (EVO) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall

Evotec Receives Grants to Advance Tuberculosis Treatment

Evotec Announces New Nomination to Board of Directors

Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer

Search stocks

Evotec SE (EVO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Evotec SE (EVO)

Evotec SE (EVO) Q1 2026 Earnings Call Transcript

Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall

Evotec Receives Grants to Advance Tuberculosis Treatment

Evotec Announces New Nomination to Board of Directors

Evotec SE to Announce First Quarter 2026 Results on May 6, 2026

Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer

Evotec SE (EVO) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall

Evotec Receives Grants to Advance Tuberculosis Treatment

Evotec Announces New Nomination to Board of Directors

Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer

Evotec SE (EVO) Q1 2026 Earnings Call Transcript

Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall

Evotec Receives Grants to Advance Tuberculosis Treatment

Evotec Announces New Nomination to Board of Directors

Evotec SE to Announce First Quarter 2026 Results on May 6, 2026

Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer

Evotec SE (EVO) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall

Evotec Receives Grants to Advance Tuberculosis Treatment

Evotec Announces New Nomination to Board of Directors

Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer